Puretech Health plc (PRTC) Ordinary 1p

- Add to watchlist
- Create an alert
- This stock can be held in a




124.20p
128.80p
238.50p
£300.72 million
123.80p
122.60p
100.40p
7.80
2.20p (1.75%) Previous:
2.20p
111,610
n/a
7,500
Performance
1 week 1W | 3.84% | 1 year 1Y | 43.86% |
---|---|---|---|
1 month 1M | 21.55% | 2 years 2Y | 42.3% |
3 months 3M | 13.3% | 3 years 3Y | 22.52% |
6 months 6M | 20.15% | 5 years 5Y | 48.9% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
Year ending: | 31/12/2024 | 31/12/2023 |
---|---|---|
Revenue ($m) | 4.83 | 3.33 |
Profit before tax ($m) | 23.77 | (36.10) |
Adjusted EPS (¢): | 21.00 | (24.00) |
P/E ratio | 9.50 | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: US dollar
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
PureTech financials improve in a year of clinical, regulatory milestones
30 April 2025 10:35
-
London close: Stocks weaker ahead of key central bank decisions
16 December 2024 15:35
-
PureTech hails "exciting" results from lung disease trial
16 December 2024 09:30
-
PRTC Publishes Research on Unmet IPF Patient Needs
9 May 2025 12:00
-
PRTC To Present Ph2b IPF Results at ATS Conference
1 May 2025 12:00
-
Final Results
30 April 2025 07:00
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.